Cybin price target lowered to $55 from $150 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Cybin (CYBN) to $55 from $150 and keeps a Buy rating on the shares. Strong clinical execution, commercial groundwork, and financial strengthening leave Cybin well-positioned ahead of two major 2026 readouts, the firm says. The increased share count from the recent financing, normalization of expenses in Wainwright’s model, and fine-tuning its expected CYB003 launch to 2028 and CYB004 launch to 2029 resulted in a revised price target Wainwright adds.